ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation ("Algoma† or "the Company† of three new methanol-ready Kamsarmax-sized ocean belt self-unloading vessels. With this addition, the Company will have an ownership interest in 100 vessels across its global fleet, a historic milestone that underscores its leadership in long-term growth in diversified short sea shipping markets. "This is a proud moment on two fronts: t. ...

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund (Investor Shares) returned 13.29% (net of fees) in the quarter, compared to the Russell Midcap Growth Index’s 18.20% return. Stock selection in the Industrials and Information Technology sectors negatively impacted the performance, while holdings in the Financials sector contributed. In addition, please check the fund ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day "window shop†period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The "window shop†period expired at 11:59 p.m., Eastern Time, on September 19, 2025, and no competing acquisition proposal was receive. ...

Yunqi Capital, an investment management firm and 5.1% shareholder of Staar Surgical Company (NASDAQ:STAA), announced its opposition to the company’s proposed sale to Alcon (NYSE:ALC) on the terms announced on August 5. Yunqi Capital stated that it believes the $28 per ...

HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital†), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR†) (NASDAQ:STAA), today announced its opposition to the Company's proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025. Yunqi Capital released the following open letter to fellow STAAR shareholders explaining why it opposes the transaction: September 22, 2025. ...

Key Takeaways Alcon's Surgical unit grew 2% in Q2, aided by consumables strength and new product launches. ALC's Vision Care is fueled by contact lens advances, FDA approval of TRYPTYR, and strong eye drop sales. Macroeconomic headwinds, tariffs, and rising costs weighed on Alcon's Q2 results and outlook. Alcon’s (ALC) Vision Care business continues to gain from its diverse portfolio of contact lenses and ocular health products. Additionally, growth momentum within the Surgical business is poised to boost t ...

Key Takeaways Alcon unveiled UNITY VCS study results showing superior efficiency in cataract and vitreoretinal surgery.UNITY VCS outperformed CONSTELLATION with 16% workflow efficiency and faster setup and teardown times. UNITY VCS cut cataract turnover 6% versus CENTURION, with 35% less energy use and 8% less ultrasound time. Alcon (ALC) unveiled results from time and motion studies demonstrating superior efficiency with the UNITY Vitreoretinal Cataract System (VCS) for vitreoretinal and cataract surgery c ...

并购交易 - STAAR Surgical Company与Alcon达成最终合并协议 Alcon将以每股28美元现金价格收购STAAR [1] - STAAR董事会一致认为该合并符合公司及股东最佳利益 强烈建议股东投票支持合并提案 [1] - 特别股东大会将于2025年10月23日上午8:30以虚拟方式举行 旨在通过合并协议 [1] 交易背景与估值依据 - 公司认为Alcon提供的估值超过STAAR作为独立实体在可预见未来所能实现的价值 [1] - 决策基于STAAR较低的增长率及其对估值产生的负面影响 [1] - 公司面临服务市场的重大竞争和宏观挑战 [1] 区域市场风险 - 业务高度集中于中国市场 该地区面临显著经济不确定性 [1] - 尽管公司已采取应对措施 但中国区销售趋势仍持续下滑 [1]

核心产品 - LumiThera的核心创新是一种供眼科医生使用的设备 该设备旨在改善视力并减缓视力丧失 [1] - 该设备主要针对干性年龄相关性黄斑变性患者 [1]

公司业务发展 - 公司负责所有转录相关项目的开发 [1] - 公司每季度发布数千份季度财报电话会议记录 [1] - 公司持续扩大转录内容覆盖范围 [1]